MHC binding peptide - SYFPEITHI

SYFPEITHI MHC binding peptide: for immune reactivity studies and Major Histocompatibility Complex (MHC) ligand assays. Peptides binding MHC molecules play a key role in cell-mediated immunity, as T-cells are only able to recognize foreign antigens when bound to an MHC protein. Antigenic peptide are categorized as endogenous whether they are derived from viruses, intracellular bacteria, or protozoan parasites; or as exogeneous if they originate from pathogens that replicate outside of the cell. In order to trigger adaptive immunity towards a specific condition, peptides able to bind to all kind of MHC molecules are needed. Among these peptides, SYFPEITHI has been tested in multiple MHC ligand assays and its ability to bind both MHC class I and II molecules was demonstrated (see IEDB SYFPEITHI epitope summary). SYFPEITHI is a linear peptide from Tyrosine-protein kinase JAK1 (UniProt: P23458) in Humans and from Tyrosine-protein kinase (UniProt: B1ASP2) and Tyrosine-protein kinase JAK1 (UniProt: P52332) in mice. Tyrosine kinase is a cellular enzyme catalyzing the transfer of a phosphate group from ATP to a protein. These proteins are important mediators to switch « on » or « off » biological processes, such as cellular growth, differentiation, metabolism and apoptosis, in response to external and internal stimuli. Among tyrosine kinases, Janus kinase 1 (JAK1) is an essential protein interacting with type I and type II cytokines, especially involved in T-cells expansion. Epitope screening of Human and Mouse JAK1, as well as mouse Tyrosine Kinase, highlighted SYFPEITHI peptide as an interesting epitope to induce immune reactivity. The interest for MHC binding peptides stems from the growing importance for T-cells to address various diseases. Moreover, studies showed that SYFPEITHI might be used as Tumor Antigen (TA) in vaccine development to treat cancer.